Post Polycythemia Vera Myelofibrosis Pipeline Insight
DelveInsight’s, “Post-Polycythemia Vera Myelofibrosis – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 15+ pipeline drugs in Post-Polycythemia Vera Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Post-Polycythemia Vera Myelofibrosis Understanding
Post-Polycythemia Vera Myelofibrosis: Overview
Post-Polycythemia Vera Myelofibrosis is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells which can lead to health problems like sluggish circulation and blood clots. Polycythemia Vera is caused by a genetic change in stem cells, the stem cells that have genetic changes are the ones that grow into red blood cells, white blood cells, and platelets. The mutation causes them to divide and grow out of control. It is more common in elderly.
Symptoms develops very slowly and may include:
- Deep venous thrombosis
- Lack of concentration
- Scarring in the bone marrow
Post-Polycythemia Vera Myelofibrosis may be symptomatic or asymptomatic. The symptoms usually develop very slowly. Physical exam findings are non-specific, but may include enlarged liver or spleen, plethora, or gouty nodules. The diagnosis is often suspected on the basis of laboratory tests. Diagnostic procedures involve: Blood tests which may reveal more blood cells than normal, Bone marrow aspiration, specific gene testing.
There is no cure for Post-Polycythemia Vera Myelofibrosis. Treatment focuses on reducing the risk of complications. The treatment generally eases the symptoms. The most common treatment for Post-polycythemia Vera Myelofibrosis is having frequent blood withdrawals, using a needle in a vein (phlebotomy). This decreases the number of excess blood cells. Some medications that reduce the number of red blood cells include: Hydroxyruea (Droxia, Hydrea),Interferon alfa-2b (Intron A), Ruxolitinib (Jakafi), Busulfan.
The companies and academics are working to assess challenges and seek opportunities that could influence Post-Polycythemia Vera Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Post-Polycythemia Vera Myelofibrosis.
Post-Polycythemia Vera Myelofibrosis Emerging Drugs Chapters
This segment of the Post-Polycythemia Vera Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Post-Polycythemia Vera Myelofibrosis Emerging Drugs
Pacritinib: CTI BioPharma Corp.
Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2 and IRAK1 developed for the treatment of patients with myeloproliferative diseases. Pacritinib’s unique MOA (JAK2/IRAK1) may allow for reductions of both splenomegaly and constitutional systems and may reduce the risk of cytopenias and immune dysfunction associated with other JAK inhibitors. Parcitinib is in Phase III stage of development led by CTI Biopharma Corp.
Momelotinib: Sierra Oncology, Inc
Momelotinib, Sierra's lead drug candidate in Phase II, a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2 and ACVR1 inhibitor.
Bomedemstat: Imago Biosciences
Bomedemstat is an orally available small molecule discovered and developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem/progenitor cells. Bomedemstat is an investigational agent currently being evaluated in Phase II ongoing clinical trials for Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF).
KRT-232: Kartos Therapeutics, Inc.
KRT-232 is a novel, potent, and selective oral MDM2 inhibitor. KRT-232 is currently in phase II stage of clinical trials led by Kartos Therapeutics. The MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients with Myelofibrosis (MF), Post-Polycythemia Vera Myelofibrosis, Acute Myeloid Leukemia (AML), and Merkel Cell Carcinoma (MCC).
Further product details are provided in the report……..
Post-Polycythemia Vera Myelofibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Post-Polycythemia Vera Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Post-Polycythemia Vera Myelofibrosis
There are approx. 20+ key companies which are developing the therapies for Post-Polycythemia Vera Myelofibrosis. The companies which have their Post-Polycythemia Vera Myelofibrosis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Sierra Oncology Corp.and others.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III )
- Mid-Stage products (Phase II)
- Early-stage products ( Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Post-Polycythemia Vera Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Post-Polycythemia Vera Myelofibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Post-Polycythemia Vera Myelofibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-Polycythemia Vera Myelofibrosis drugs.
Post-Polycythemia Vera Myelofibrosis Report Insights
- Post-Polycythemia Vera Myelofibrosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Post-Polycythemia Vera Myelofibrosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Post-Polycythemia Vera Myelofibrosis drugs?
- How many Post-Polycythemia Vera Myelofibrosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Post-Polycythemia Vera Myelofibrosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Post-Polycythemia Vera Myelofibrosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Post-Polycythemia Vera Myelofibrosis and their status?
- What are the key designations that have been granted to the emerging drugs?